On August 12th, 2026, Radar Healthcare, a provider of risk, quality and compliance software for the health and social care sectors, formally announced its acquisition of patient experience and patient-reported outcomes platform Cemplicity. Backed by private equity firm Marlin Equity Partners, a global investment firm with over $9 billion in capital commitments, Radar Healthcare has executed this transaction as part of an aggressive platform-expansion strategy.

Operating in the lower to middle market, specifically targeting companies with Enterprise Values (EV) ranging from $25 Million to $250 Million, Nelson Advisors LLP represents a prime example of this specialised advisory model. Headquartered in London, the firm leverages more than 15 years of operational healthcare technology experience derived from founding, funding, scaling and exiting HealthTech ventures since 2011, combining institutional investment banking execution with

Hims & Hers Health, Inc. has undergone a fundamental structural evolution, transitioning from a direct-to-consumer marketplace for stigmatised wellness products into a technology-driven, global healthcare platform. Originally launched to provide streamlined access to generic therapies in hair care and sexual health, the company has expanded its clinical breadth to encompass dermatology, mental health, weight management, cardiovascular care, hormone optimisation and direct-to-

The convergence of wearable biometric sensors, continuous physiological monitoring, and advanced natural language processing has catalysed a fundamental shift in personal health management. A rapidly growing cohort of quantified-self practitioners, popularly termed "datamaxxers", is transforming personal wellness by systematically ingesting granular biometrics, clinical records, and behavioural logs into conversational artificial intelligence platforms. Rather than relying on

On August 11th, 2026, Flagler Health announced the completion of a $50 Million Series B financing round, bringing its total capital raised to $63 Million. The investment was led by Bessemer Venture Partners, with participation from a syndicate of institutional venture investors including SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Ventures and Offscript. Legal counsel for the financing transaction was executed by Wilson Sonsini Goodrich & Rosati,

Between co-founding Zesty in 2012 and building it into one of the UK's leading patient portals, negotiating a Value Added Reseller agreement with Cerner that took three years to close and multiplied our annual revenue significantly, and raising capital from US, European & UK Venture Capital Funds across five very different vintages, I accumulated scar tissue that I now put to work advising founders, investors and boards at Nelson Advisors.

The European Union has embarked on an ambitious regulatory effort to establish digital and data sovereignty across critical economic sectors. At the centre of this strategy lies the European Health Data Space (EHDS) Regulation (EU) 2025/327 which officially entered into force on March 26th, 2025. By creating a single market for electronic health data, the European Commission seeks to empower citizens, streamline cross-border clinical care and unleash secondary health data re

Healthcare enterprises operate in an environment where legacy Electronic Health Record (EHR) platforms, such as Epic, Oracle Cerner, Allscripts and NextGen, serve as the foundational bedrock of clinical operations. These systems were engineered specifically for clinical charting, regulatory documentation, diagnostic order entry and transactional billing. However, legacy EHR platforms were not designed to deliver dynamic, personalised patient engagement, modern omni channel co

On August 5th, 2026, iRhythm Holdings, Inc. (NASDAQ: IRTC) executed a definitive merger agreement to acquire privately held Vital Connect, Inc. for an aggregate transaction value of approximately $287.5 million. The transaction consideration comprises $237.5 million in cash, funded directly from iRhythm's existing balance sheet, alongside $50.0 million in iRhythm common stock. To maintain operational continuity and support VitalConnect’s working capital requirements through t

The biopharmaceutical and digital health sectors are undergoing a structural convergence driven by asymmetric financial pressures, shifting commercial models, and evolving regulatory frameworks. Biopharma is entering an aggressive loss of exclusivity (LOE) cycle, frequently designated the "super patent cliff," in which an estimated $200 Billion to $300 Billion in annual global branded revenues will expire between 2025 and 2030. This impending revenue contraction coincides wit

Telehealth has completed its transition from a speculative, venture-backed growth category to permanent healthcare infrastructure. Following the unprecedented surge during the early stages of the COVID-19 pandemic, when virtual care claims spiked to 78 times pre-pandemic levels, utilization has settled into a durable equilibrium approximately 38 times higher than pre-2020 baselines. Outpatient and office visit virtualisation has stabilised between 13% and 17% across clinical

The global healthcare landscape is experiencing a re-evaluation of women’s health technology (commonly termed "femtech"). Historically treated as a niche sector concentrated around direct-to-consumer (DTC) reproductive apps and fertility solutions, women’s health tech has expanded into a complex, multi-specialty asset class spanning biopharma, AI-driven diagnostics, maternal care, midlife health, and chronic disease management.

The European healthcare technology (HealthTech) and medical technology (MedTech) landscape has entered an era of industrial maturity. Following a post-pandemic recalibration, market dynamics reflect a structural shift characterised as "The Great Rationalisation," wherein speculative top-line expansion has been replaced by strict underwriting standards centered on clinical pathway integration, regulatory fortification, margin sustainability, and demonstrated return on investme

The global financial advisory landscape for Healthcare Technology (HealthTech), Medical Technology (MedTech), and Healthcare Artificial Intelligence (AI) has entered a profound phase of structural realignment, recognised across institutional corporate finance as the "Great Rationalisation". Departing from the unconstrained, growth at all costs venture capital environment of the early 2020s, enterprise valuations across digital health are governed by clinical utility, regulato

Driven by corporate portfolio realignments and substantial private equity capital reserves, global healthcare M&A transaction value reached $546.7 billion in 2025, representing a 38% year-over-year increase. Within Europe, private equity healthcare buyout value scaled to $80.9 billion in 2025 and is projected to surpass $95.0 billion in 2026. While mega-cap transactions exceeding $1 billion in Enterprise Value (EV) attract headline coverage, intense competition among bulge-br